Adaptimmune Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Share-based compensation

Share-based compensation

3 Months Ended

Mar. 31, 2022

Note 12 — Share-based compensation

The following table shows the total share-based compensation expense included in the unaudited consolidated statements of operations (in thousands):


	Three months ended
	March 31,
	2022		2021
Research and development	$	2,523	$	2,375
General and administrative		3,063		2,959
	$	5,586	$	5,334

The following table shows information about share options and options which have a nominal exercise price (similar to restricted stock units (RSUs)) granted:


	Three months ended
	March 31,
	2022		2021
Number of options over ordinary shares granted		22,876,464		14,803,056
Weighted average fair value of ordinary shares options	$	0.43	$	0.75
Number of additional options with a nominal exercise price granted		17,688,432		12,663,792
Weighted average fair value of options with a nominal exercise price	$	0.59	$	1.03